Antibody-Based Therapy Research

Antibodies against proteins typically expressed in conditions of immune cell dysregulation can be used in research to study disease mechanisms and further the development of other treatment options. Access to reference therapeutic antibodies for research use is limited and expensive so investigators need a generic surrogate, termed a biosimilar. 

Biosimilar antibodies are typically an amino acid sequence copy of their originator FDA-approved therapeutic antibodies, called reference products. They generally have the same mechanism of action as the reference drug and  are used in research to understand how therapeutic antibodies work, with the goal of designing the next generation of antibody-based biologics. BD has developed research-grade biosimilars to help further research studies in this field.